Abstract: Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.

Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

Abstract: A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a delivery device. Actuation of the foam generating mechanism entraps gaseous bubbles from the gas in the liquid thereby forming a foam. The therapeutic agent is dispersed in the foam which has an expanded configuration adapted to fill a nasopharyngeal space and deliver the therapeutic agent to the mucosa targets. The delivery device is for delivering the foam to the nasopharyngeal space. The foam may also have a collapsed configuration for removal from the nasopharyngeal space or for concentration of the therapeutic agent onto the mucosa.

Abstract: Pathology of the human knee can arise from excessive and/or uneven loading of regions within the joint. Methods and apparatus are disclosed that enable displacement of soft tissue around the knee, without displacing or severing bone thereby altering the mechanical load distribution within the joint in a less invasive manner than previous techniques.

Abstract: A system for delivering a therapeutic agent to nasopharyngeal mucosa tissue has a shaft, a porous pad of compliant material coupled to the shaft near the distal end, and a drug reservoir. The porous pad is configured to expand from a contracted configuration to an expanded configuration. The expanded configuration is adapted to engage and conform to the mucosa tissue in a nasal cavity, and the contracted configuration has a size suitable for introduction into the nasal cavity. The drug reservoir holds a therapeutic agent and is at least partially covered by the porous pad. The drug reservoir is configured to release a fixed volume of the therapeutic agent into the porous pad within a period of less than about 120 minutes, and has a wall with a plurality of channels fluidly coupled with the porous pad.

Abstract: Protheses and methods for treating canine cruciate ligament disease are disclosed comprising placement of a specifically configured implant on the femur or tibia to displace targeted muscle or connective tissue associated with the stifle joint so as to reduce cranial tibial thrust.

Abstract: Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.

Abstract: Various devices, systems and methods for knotless suturing of tissue are disclosed. These devices allow sutures to be anchored to bone, and more specifically provide a suture anchor which eliminates the need for knotting the suture. Thus, damaged tissue may be re-attached to a substrate tissue. The anchors have a minimum of moving parts may be suited to being a single molded polymer construction. The anchors will find particular utility in hip and shoulder arthroscopy, e.g. labral re-attachment and similar procedures.

Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

Abstract: A knotless suture anchoring system includes an outer anchor having a central channel and a distal tip adapted to penetrate tissue. An inner anchor is positionable in the central channel of the outer anchor and a locking feature on one or both of the inner and outer anchors retains the inner anchor within the central channel. A continuous length of suture is coupled with the inner and outer suture anchors and has a free end. At least one of the inner and the outer anchors also has a cinching mechanism that allows the suture to be tensioned by passage of the suture through the cinching mechanism in a first direction while movement of the suture through the cinching mechanism in a second direction opposite the first direction is constrained.

Abstract: Devices and methods for treating aneurysms, such as abdominal aortic aneurysms (“AAA”) generally include one or more stent-graft devices. Some embodiments include self-expanding and/or balloon-expandable stent components and one or more graft components coupled with the stent components. Using various combinations of self-expanding stent members, balloon-expandable stent members, graft members, and/or anchoring members enhances the anchoring abilities of a stent-graft device to prevent leakage around it, and may further allow the device to be adjusted after placement at a site for treatment. Some embodiments further include a skirt graft member for further prevention of leakage and/or device slippage.

Abstract: A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a delivery device. Actuation of the foam generating mechanism entraps gaseous bubbles from the gas in the liquid thereby forming a foam. The therapeutic agent is dispersed in the foam which has an expanded configuration adapted to fill a nasopharyngeal space and deliver the therapeutic agent to the mucosa targets. The delivery device is for delivering the foam to the nasopharyngeal space. The foam may also have a collapsed configuration for removal from the nasopharyngeal space or for concentration of the therapeutic agent onto the mucosa.

Abstract: Methods and apparatus are provided that enable a physician to image tissue within the body that is to be ablated, and then to ablate that tissue using a device having an ultrasound imaging system and an aligned high intensity focused ultrasound system.

Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

Abstract: A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a delivery device. Actuation of the foam generating mechanism entraps gaseous bubbles from the gas in the liquid thereby forming a foam. The therapeutic agent is dispersed in the foam which has an expanded configuration adapted to fill a nasopharyngeal space and deliver the therapeutic agent to the mucosa targets. The delivery device is for delivering the foam to the nasopharyngeal space. The foam may also have a collapsed configuration for removal from the nasopharyngeal space or for concentration of the therapeutic agent onto the mucosa.

Abstract: A system for delivering a therapeutic agent to nasopharyngeal mucosa tissue has a shaft, a porous pad of compliant material coupled to the shaft near the distal end, and a drug reservoir. The porous pad is configured to expand from a contracted configuration to an expanded configuration. The expanded configuration is adapted to engage and conform to the mucosa tissue in a nasal cavity, and the contracted configuration has a size suitable for introduction into the nasal cavity. The drug reservoir holds a therapeutic agent and is at least partially covered by the porous pad. The drug reservoir is configured to release a fixed volume of the therapeutic agent into the porous pad within a period of less than about 120 minutes, and has a wall with a plurality of channels fluidly coupled with the porous pad.

Abstract: Devices and methods for treating aneurysms, such as abdominal aortic aneurysms (“AAA”) generally include one or more stent-graft devices. Some embodiments include self-expanding and/or balloon-expandable stent components and one or more graft components coupled with the stent components. Using various combinations of self-expanding stent members, balloon-expandable stent members, graft members, and/or anchoring members enhances the anchoring abilities of a stent-graft device to prevent leakage around it, and may further allow the device to be adjusted after placement at a site for treatment. Some embodiments further include a skirt graft member for further prevention of leakage and/or device slippage.

Abstract: Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.

Abstract: Devices and methods for treating aneurysms, such as abdominal aortic aneurysms (“AAA”) generally include one or more stent-graft devices. Some embodiments include self-expanding and/or balloon-expandable stent components and one or more graft components coupled with the stent components. Using various combinations of self-expanding stent members, balloon-expandable stent members, graft members, and/or anchoring members enhances the anchoring abilities of a stent-graft device to prevent leakage around it, and may further allow the device to be adjusted after placement at a site for treatment. Some embodiments further include a skirt graft member for further prevention of leakage and/or device slippage.

Abstract: Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.